Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis

Tomasz Siwek; Katarzyna Jezierska-Woźniak; Stanisław Maksymowicz; Monika Barczewska; Mariusz Sowa; Wanda Badowska; Wojciech Maksymowicz

doi:10.12659/MSM.927484

10 December 2020 : Clinical Research

Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis

Tomasz Siwek^12ABDEFG*, Katarzyna Jezierska-Woźniak^3ABDEF, Stanisław Maksymowicz^4BCDEF, Monika Barczewska^56BD, Mariusz Sowa^57B, Wanda Badowska^8B, Wojciech Maksymowicz^57ADG

DOI: 10.12659/MSM.927484

Med Sci Monit 2020; 26:e927484

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Table 1 Demographic and statistical data.

	Age	Sex	Clinical form of ALS	Progression rate	Monthly decrease in ALSFRS-R scores before treatment	Monthly decrease in ALSFRS-R scores after treatment	Change in progression rate
Patient 1	41	F	Limb-onset	Slow	0.3	1.0	Increased
Patient 2	46	M	Limb-onset	Slow	0.6	0.7	No change
Patient 3	53	F	Bulbar	Fast	2.9	0.3	Decreased
Patient 4	43	M	Limb-onset	Slow	0.7	0.8	No change
Patient 5	53	F	Bulbar	Slow	0.3	1.3	Increased
Patient 6	72	M	Limb-onset	Slow	0.7	0.7	No change
Patient 7	54	M	Bulbar	Slow	0.3	0.3	No change
Patient 8	47	M	Limb-onset	Fast	1.2	0.2	Decreased

Back to the Article

Repeat Administration of Bone Marrow-Derived Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis

Your Privacy